Prelude Therapeutics Q2 EPS $(0.14) Beats $(0.20) Estimate, Sales $5.704M

Prelude Therapeutics, Inc.

Prelude Therapeutics, Inc.

PRLD

0.00

Prelude Therapeutics (NASDAQ: PRLD) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is a 65.85 percent increase over losses of $(0.41) per share from the same period last year. The company reported $5.704 million in sales this quarter.